# Zoledronic Acid in Preventing Osteoporosis in Patients Undergoing Donor Stem Cell Transplant

> **NCT00321932** · PHASE2 · COMPLETED · sponsor: **University of Minnesota** · enrollment: 61 (actual)

## Conditions studied

- Leukemia
- Lymphoma
- Myelodysplastic Syndromes
- Osteoporosis
- Ovarian Cancer

## Interventions

- **DIETARY_SUPPLEMENT:** calcium
- **DIETARY_SUPPLEMENT:** cholecalciferol
- **DRUG:** zoledronic acid

## Key facts

- **NCT ID:** NCT00321932
- **Lead sponsor:** University of Minnesota
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2005-07
- **Primary completion:** 2011-03
- **Final completion:** 2012-03
- **Target enrollment:** 61 (ACTUAL)
- **Last updated:** 2017-03-09


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00321932

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00321932, "Zoledronic Acid in Preventing Osteoporosis in Patients Undergoing Donor Stem Cell Transplant". Retrieved via AI Analytics 2026-07-30 from https://api.ai-analytics.org/clinical/NCT00321932. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*